Exelixis

$19.48 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Exelixis

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Stock Analysis

last close $19.48
1-mo return -7.5%
3-mo return -1.6%
avg daily vol. 2.24M
52-week high 23.4
52-week low 15.5
market cap. $6.9B
forward pe 19.6
annual div. -
roe 14.2%
ltg forecast 46%
dividend yield -
annual rev. $1.5B
inst own. 89.1%
baraka

Subscribe now for daily local and international financial news

Subscribe